Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704028 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
NCT00704028 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 161 participants.
The verdict
NCT00704028, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
Interventions
- DRUG Ferric Carboxymaltose
- DRUG Iron Dextran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704028
The ClinicalTrials.gov registry entry for NCT00704028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose is the first listed.
NCT00704028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00704028 about?
NCT00704028 is a clinical study titled "Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia". The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
What is the current status of trial NCT00704028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2008-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00704028?
The interventions under investigation include: Ferric Carboxymaltose (DRUG), Iron Dextran (DRUG).
Who is sponsoring clinical trial NCT00704028?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.